Company Name, Ticker, Suppliers, else..

Scpharmaceuticals Inc (NASDAQ: SCPH)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Scpharmaceuticals Inc 's

Name: Scpharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SCPH Sales vs. its Competitors Q2 2025

Comparing the current results to its competitors, Scpharmaceuticals Inc reported Revenue increase in the 2 quarter 2025 by 99.17 % year on year.
The sales growth was above Scpharmaceuticals Inc 's competitors' average revenue growth of 3.56 %, achieved in the same quarter.

• List of SCPH Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Scpharmaceuticals Inc recorded a net loss, despite income increase by most of its competitors of 0 %

<< SCPH Stock Performance Comparisons

<< See the full list of SCPH competitors

Overall company Market Share Q2 2025

Due to outstanding performance in Overall company, revenue grew by 99.17 % Scpharmaceuticals Inc improved its market share, to approximately 0.04 %. << More on SCPH Market Share.

*Market share is calculated based on total revenue.

SCPH's Stock Performance relative to its Competitors

Publicly Traded Peers of Scpharmaceuticals Inc

Legend Biotech Corporation
Share Performance

-40.19%

This Quarter

Legend Biotech Corporation

Profile

Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.

More about Legend Biotech Corporation's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 7,933.159 mill.	$ 1,751.341 mill.	$ -296.800 mill.

Lipocine Inc
Share Performance

+11.87%

This Quarter

Lipocine Inc

Profile

Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.

More about Lipocine Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 20.132 mill.	$ 1.569 mill.	$ -11.851 mill.

Lexicon Pharmaceuticals Inc
Share Performance

+96.49%

This Year

Lexicon Pharmaceuticals Inc

Profile

Lexicon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative drugs. Their business model revolves around identifying potential drug targets, conducting research and preclinical studies to validate these targets, and subsequently developing drugs through clinical trials for various therapeutic areas. They also collaborate with pharmaceutical companies for joint development and commercialization efforts, aiming to bring these drugs to market and improve patient outcomes.

More about Lexicon Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 896.538 mill.	$ 69.643 mill.	$ -26.090 mill.

Mineralys Therapeutics Inc
Share Performance

+10.20%

Over The Past 5 Days

Mineralys Therapeutics Inc

Profile

Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.

More about Mineralys Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,390.157 mill.	$ - mill.	$ -349.576 mill.

Keenova Therapeutics Plc
Share Performance

0.00%

One Year

Keenova Therapeutics Plc

Profile

Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.

More about Keenova Therapeutics Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 13.472 mill.	$ 1,413.000 mill.	$ -573.100 mill.

69 more competitors available

Sources: Scpharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 5, 2026 3:39 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Scpharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.